TABLE 1.
Descriptive characteristics of the participants with PD
| Participant | Age | Years since diagnosis | Sex | PD medications | Reduced loudness ratinga | Reduced articulatory precision ratinga |
|---|---|---|---|---|---|---|
| PD1 | 70 | 10 | F | Selegiline, Pramipexole | 1.3 | 1.8 |
| PD2 | 71 | 5 | M | C-dopa/L-dopa, Pramipexole, Entacapone | 1.7 | 1.8 |
| PD3 | 73 | 5 | F | C-dopa/L-dopa, Pramipexole | 4.0 | 1.5 |
| PD4 | 75 | 15 | M | C-dopa/L-dopa | 4.7 | 3.0 |
| PD5 | 80 | 6 | F | C-dopa/L-dopa, Entacapone, Ropinirole | 1.7 | 1.0 |
| PD6 | 75 | 5 | F | C-dopa/L-dopa, Bromocriptine | 1 | 1.0 |
| PD7 | 77 | 4 | M | C-dopa/L-dopa | 5.8 | 3.3 |
| PD8 | 79 | 5 | M | C-dopa/L-dopa, Entacapone, Ropinirole | 4.7 | 3.0 |
| PD9 | 70 | 6 | M | C-dopa/L-dopa | 1.3 | 2.3 |
| PD10 | 70 | 5 | F | C-dopa/L-dopa, Bromocriptine | 4.0 | 2.0 |
| PD11 | 79 | 5 | M | C-dopa/L-dopa, Mirapex | 3.0 | 1.5 |
| PD12 | 82 | 4 | M | C-dopa/L-dopa, Amantadine | 1.0 | 1.7 |
| PD13 | 74 | 5 | M | C-dopa/L-dopa, Selegiline, Pramipexole | 1.7 | 1.8 |
| PD14 | 62 | 5 | M | C-dopa/L-dopa, Amantadine | 1.7 | 1.5 |
| PD15 | 67 | 12 | M | C-dopa/L-dopa | 2.7 | 1.3 |
| PD16 | 71 | 6 | M | C-dopa/L-dopa | 2.7 | 1.0 |
a
Seven-point perceptual rating scale: 1 =normal; 2–3 =mild severity; 4–5 =moderate; and 6–7 =severe.
PD, Parkinson’s disease; F, female; M, male; C-dopa, carbidopa; L-dopa, levodopa.